Improving islet transplantation for type 1 diabetes treatment
Official title: Islet dosing and loading density in injection molded macroencapsulation devices
Funded at Immunoshield Therapeutics INC. · NIH-10716174 · Data updated 2026-11-12
This study is working on making islet transplantation a better option for people with type 1 diabetes by creating special devices that protect the transplanted cells from the immune system and help them get the oxygen they need to thrive.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immunoshield Therapeutics INC. NIH-funded |
| Lab location | 1 site (Chandler, United States) |
| Project start | August 4, 2023 |
| Project end | August 3, 2025 |
| Funding year | 2023 |
| Award (this year) | $298,364 |
| NIH project number | 1R43DK136496-01 |
| Project ID | NIH-10716174 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with type 1 diabetes who may benefit from islet transplantation.
✕Less likely to help
Patients with type 2 diabetes or those who are not candidates for islet transplantation may not receive benefits from this research.
What this research studies
This research focuses on enhancing the effectiveness of islet transplantation, a potential therapy for type 1 diabetes. It aims to address the challenges of immune response and donor shortages by developing macroencapsulation devices that protect transplanted islets from immune rejection. The study employs advanced computational modeling to design these devices for better oxygen transport, which is crucial for the survival and function of the islets. By improving the safety and efficacy of this treatment, the research seeks to make islet transplantation a more viable option for patients with type 1 diabetes.
Why it matters
Potential benefit: If successful, this research could lead to more effective islet transplantation therapies, potentially reducing or eliminating the complications associated with type 1 diabetes.
How similar studies have gone: While there have been promising preclinical studies on islet encapsulation, this specific approach using macroencapsulation devices is still being explored and has not yet achieved widespread clinical success.
Where this research is happening
-
Immunoshield Therapeutics INC.
Chandler, United States Active
Researchers
- Principal investigator: Snir, Oren — Immunoshield Therapeutics INC.
- Study coordinator: Snir, Oren
Related research
Other NIH-funded projects on the same topics.
-
Hydrogel islet device to help people with type 1 diabetes
A new device designed to protect insulin-producing cells transplanted into people with type 1 diabetes could reduce or replace insulin injections.
-
Injectable hydrogel devices to protect transplanted insulin-producing cells
Researchers are developing an injectable hydrogel device to shield transplanted insulin-making cells so people with type 1 diabetes might reduce or stop daily insulin injections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.